Company Overview and News

310
Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

2h biospace
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
ZYME BLCM NLNK PIRS ARMO RCUS INO IDRAW INCY SRNE JNCE IDRA FATE MRTX CLDX

161
Institutional Top Ideas: Great Point Partners

2018-06-19 seekingalpha
Great Point Partners has high returns of late and a significantly concentrated portfolio while avoiding extreme overweighting we´ve seen with certain other funds.
SGEN DBV IDRAW IDRA MRTX CASC

97
Idera Stock Has Declined Since Failure Of Phase 2 Trial In Rare Disease, But That Wasn't The Golden Ticket Indication

2018-06-19 seekingalpha
The true value in Idera lies in the combination study using IMO-2125 and Yervoy in patients with anti-PD-1 refractory melanoma.
IDRAW IDRA BCRX

234
Institutional Top Ideas: Cormorant Asset Management

2018-06-16 seekingalpha
Cormorant Asset Management has overweighted its top 5 positions (especially first 3) and a relatively high turnover compared to other funds we´ve looked at.
OMER VSAR RXDX MDGL IDRAW IDRA GLMD

112
Idera Stock Down, Study on Dermatomyositis Candidate Fails

2018-06-13 zacks
Idera Pharmaceuticals Inc (IDRA - Free Report) announced that the phase II clinical study, evaluating its pipeline candidate, IMO-8400, for dermatomyositis — a rare inflammatory skin disease — fell short of meeting the primary endpoint.
IDRAW IDRA CRSP GHDX BCRX

97
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

2018-06-13 globenewswire
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 10:00 A.M. E.T.
IDRAW IDRA BCRX

72
Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis

2018-06-12 globenewswire
EXTON, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced topline results from the Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis.
IDRAW IDRA

205
Institutional Top Ideas: EcoR1 Capital

2018-06-12 seekingalpha
Returns for EcoR1 Capital are quite impressive. It is significantly differentiated from peers with a higher percent of the portfolio in its top 10 positions and a higher turnover rate.
VSAR FGEN BBAGF IDRAW IDRA MRTX IONS PFE

80
IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-06-11 sec.gov
Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursua
IDRA

74
IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-06-11 sec.gov
Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursua
IDRA

85
IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-06-07 sec.gov
Combining Capabilities to Serve More Patients with Rare Diseases + Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Com
IDRA

75
IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-06-07 sec.gov
Combining Capabilities to Serve More Patients with Rare Diseases + Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Com
IDRA

91
IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-06-07 sec.gov
Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 and Deemed Filed Pursuant Rule14a-12
IDRA

78
IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-06-07 sec.gov
Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 and Deemed Filed Pursuant Rule14a-12
IDRA

302
Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors.
NKTR DCPH VXRT LOXO NWBO PODD MRSN SHPG BPMC MYL IMMU IDRA IOVA CTMX KITE CYHHZ BMY CYH AMAG GILD NWBOW PTN PDM K JNCE MRK GHDX ALNY

IDRA : Idera Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. Idera Pharmaceuticals use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: its Toll-like receptor, or TLR, targeting technology and its third-generation antisense, or 3GA, technology. Idera Pharmaceuticals developed these platforms based on its scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using its TLR targeting technology, Idera Pharmaceuticals design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using its 3GA technology, Idera Pharmaceuticals is developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera Pharmaceuticals believe its 3GA technology may potentially reduce the immunoto...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to IDRA / Idera Pharmaceuticals, Inc. on message board site Silicon Investor.

IDRA Baker Bros on board u0026 Vincent Millano IDRA
CUSIP: 45168K306